183270-46-4Relevant academic research and scientific papers
BISPHENYL INHIBITORS OF FARNESYLPROTEIN TRANSFERASE
-
, (2008/06/13)
The present invention comprises peptidomimetic compounds which comprise a suitably substituted aminoalkylbenzene and analine analogs, further substituted with a second phenyl ring attached via a bond, a heteroatom linker or an aliphatic linker. The instant compounds inhibit the farnesyl-protein transferase enzyme and the farnesylation of certain proteins. Furthermore, the instant farnesyl protein transferase inhibitors differ from those previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
, (2008/06/13)
The present invention comprises peptidomimetic compounds which comprise a suitably aniline and aminoalkylbenzene moieties. The instant compounds inhibit the farnesyl-protein transferase enzyme and the farnesylation of certain proteins. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
Diarylether inhibitors of farnesyl-protein transferase
Dinsmore, Christopher J.,Williams, Theresa M.,Hamilton, Kelly,O'Neill, Timothy J.,Rands, Elaine,Koblan, Kenneth S.,Kohl, Nancy E.,Gibbs, Jackson B.,Graham, Samuel L.,Hartman, George D.,Oliff, Allen I.
, p. 1345 - 1348 (2007/10/03)
The design and synthesis of simple nonpeptide inhibitors of farnesyl-protein transferase (FTase) are described. Cysteine-derived diarylether frameworks are appropriate structural replacements for the C-terminal tetrapeptide portion of the Ras protein, and possess in vitro potency against FTase. Inhibitory activity is dependent on the ring-substitution pattern, and does not require the presence of a C-terminal carboxylate group.
